Idorsia furthers the science of sleep and insomnia at World Sleep 2025

Core Insights - Idorsia Ltd is actively participating in World Sleep 2025, showcasing its commitment to advancing sleep science and insomnia treatment through various presentations and symposiums [1][6]. Company Activities - Idorsia will present eight scientific posters at World Sleep 2025, focusing on the abuse potential of insomnia therapies and the efficacy of daridorexant [1][2][3]. - The company will host an educational symposium on September 9, featuring experts discussing the relationship between insomnia and comorbid neurological or psychiatric conditions, along with new data on daridorexant [5]. Research Highlights - A significant study will analyze real-world data on the abuse potential of insomnia medications, utilizing the FDA Adverse Event Reporting System [1]. - The largest clinical characterization of insomnia patients to date will be presented, based on data from over 5,000 patients, providing insights into the disorder's impact on symptoms and functioning [4]. Industry Context - World Sleep 2025 serves as a global platform for sleep professionals to discuss advancements in sleep science and treatment, fostering collaboration among various stakeholders in the field [6][8].